id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
admet-328	Goud, Thirumal Eswara; Maddi, Srinivas; Devanna, Nayakanti; Prasad, Thatipamula Rajendra	Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters	2016	11	.pdf	application/pdf	5361	261	47	Repaglinide in the presence of atazanavir in normal rats Repaglinide in the presence of atazanavir in Diabetic rats Repaglinide in the presence of atazanavir in Hepatic impaired rats Cmax (ng/mL) 536 ± 30 1089 ± 123*** 2753 ± 7 *** 3410 ± 64 *** Tmax (h) 0.25 ± 0.00 4.0 ± 0.0 ** 4.0 ± 0.0 ** 0.5 ± 0.0 AUC0-t (ng/mL.h) 678 ± 51 8031 ± 274*** 12602 ± 227*** 18301 ± 151*** AUCtotal(ng/mL.h) 726 ± 55 8044 ± 265*** 12722 ± 209 *** 19101 ± 184*** Oral T1/2 (h) 3.0 ± 0.1 2.6 ± 0.1 3.5± 0.1 6.2 ± 0.3 ** Oral CL (mL/min/kg) 11 ± 1 1.03 ± 0.03*** 0.44 ± 0.01*** 0.65 ± 0.01 *** *** Significant at P<0.0001 compared to repaglinide control (alone) group. **Significant at P<0.0001 compared to repaglinide control (alone) group ADMET & DMPK 4(3)	cache/admet-328.pdf	txt/admet-328.txt